tradingkey.logo
搜索

Indivior PLC

INDV
添加自选
39.500USD
-0.100-0.25%
收盘 05/08, 16:00美东报价延迟15分钟
4.78B总市值
23.51市盈率 TTM

Indivior PLC

39.500
-0.100-0.25%
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-0.25%

5天

+4.89%

1月

+29.34%

6月

+27.91%

今年开始到现在

+10.09%

1年

+256.50%

TradingKey Indivior PLC股票评分

单位: USD 更新时间: 2026-05-08

操作建议

Indivior PLC当前公司基本面数据相对健康,最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理,在药品行业排名11/156位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价49.83。中期看,股价处于上升通道。近一个月,市场表现很强,技术面和基本面综合得分较高,很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

Indivior PLC评分

相关信息

行业排名
11 / 156
全市场排名
49 / 4494
所属行业
药品

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Indivior PLC亮点

亮点风险
Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
估值合理
公司最新PE估值23.51,处于3年历史合理位
机构减仓
最新机构持股121.22M股,环比减少8.77%
PRFDX持仓
明星投资者PRFDX持仓,最新持仓市值32.33K

分析师目标

根据 6 位分析师
买入
评级
49.833
目标均价
+26.16%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Indivior PLC新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Indivior PLC简介

Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
公司代码INDV
公司Indivior PLC
CEOCiaffoni (Joseph J)
网址https://www.indivior.com/en
KeyAI